Elisabeth
Ersvær
Researcher
Visit Address:
Haukeland universitetssykehus, Laboratoriebygget
5021 Bergen
Postal Address:
Postboks 7804
5021 Bergen
Phone:
+47 55 97 30 37
E-mail:
Journal articles
- 2014. Heat shock protein 90 – a potential target in the treatment of human acute myelogenous leukemia. Advances in cancer drug targets. 2: 3-53. doi: 10.2174/9781608059386114020003
- 2014. Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect. British Journal of Haematology. 164: 200-211. doi: 10.1111/bjh.12611
- 2013. Distinct single cell signal transduction signatures in leukocyte subsets stimulated with khat extract, amphetamine-like cathinone, cathine or norephedrine. BMC Pharmacology & Toxicolog. 14. 13 pages. doi: 10.1186/2050-6511-14-35
- 2013. The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia. Clinical Epigenetics. 5:13. doi: 10.1186/1868-7083-5-13
- 2013. Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions? Current Cancer Drug Targets. 13: 30-47. doi: 10.2174/1568009611309010030
- 2012. Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status - consequences and potentials for pharmacological intervention. British Journal of Haematology. 156: 468-480. doi: 10.1111/j.1365-2141.2011.08960.x
- 2011. Is there a scientific basis for a recommended standardization of collection and cryopreservation of peripheral blood stem cell grafts? Cytotherapy. 13: 1013-1024. doi: 10.3109/14653249.2011.574117
- 2011. Future perspectives: therapeutic targeting of notch signalling may become a strategy in patients receiving stem cell transplantation for hematologic malignancies. Bone Marrow Research. 2011.
- 2011. Future perspectives: should Th17 cells be considered as a possible therapeutic target in acute myeloid leukemia patients receiving allogeneic stem cell transplantation? Cancer Immunology and Immunotherapy. 60: 1669-1681. doi: 10.1007/s00262-011-1118-z
- 2011. Immunogenic apoptosis in human acute myeloid leukemia (AML): primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis. Oncology Reports. 25: 1549-1556. doi: 10.3892/or.2011.1229
- 2011. The chemokine system. in allogeneic stem-cell transplantation: a possible therapeutic target? Expert Review of Hematology. 4: 563-576. doi: 10.1586/EHM.11.54
- 2010. Minor diurnal and activity-induced variations in daytime peripheral blood platelet counts do not have any major impact on platelet yield by platelet apheresis. Transfusion and apheresis science. 43: 33-36. doi: 10.1016/j.transci.2010.05.005
- 2010. Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells. BMC Immunology. 11. doi: 10.1186/1471-2172-11-38
- 2010. PRIMARY HUMAN ACUTE MYELOGENOUS LEUKEMIA CELLS RELEASE HEAT SHOCK PROTEIN (HSP) 70 AND HSP90 DURING APOPTOSIS. Experimental Hematology. 38: S19-S20.
- 2010. PRIMARY HUMAN AML CELLS CAN EXPRESS CALRETICULIN ON THE CELL SURFACE AND RELEASE HEAT SHOCK PROTEIN 70 (HSP70) AND HSP90 DURING APOPTOSIS. Haematologica. 95: 496-497.
- 2010. Kinetics of ERK1/2 activation determine sensitivity of acute myeloid leukaemia cells to the induction of apoptosis by the novel small molecule ingenol 3-angelate (PEP005). Apoptosis (London). 15: 946-955. doi: 10.1007/s10495-010-0507-7
- 2010. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. Journal of Experimental Medicine. 207: 299-308. doi: 10.1084/jem.20091669
- 2010. Combination of Intensive Chemotherapy and Anticancer Vaccines in the Treatment of Human Malignancies: The Hematological Experience. Journal of Biomedicine and Biotechnology. 15 pages. doi: 10.1155/2010/692097
- 2010. Early pre-engraftment, functional, in vitro responsiveness of T lymphocytes in allotransplanted, acute leukemia patients: proliferation and release of a broad profile of cytokines, possibly predictive of graft-versus-host disease. European Cytokine Network. 21: 40-49. doi: 10.1684/ecn.2009.0181
- 2010. PHARMACOLOGICAL TARGETING OF THE PI3K-AKT/PKB-MTOR PATHWAY ALTERS LOCAL ANGIOREGULATION IN ACUTE MYELOGENOUS LEUKEMIA. Haematologica. 95: 266-266.
- 2010. Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release. Expert Opinion on Investigational Drugs. 19: 169-183. doi: 10.1517/13543780903485659
- 2010. Flow cytometry study of blood cell subtypes reflects autoimmune and inflammatory processes in autoimmune polyendocrine syndrome type I. Scandinavian Journal of Immunology. 71: 459-467. doi: 10.1111/j.1365-3083.2010.02397.x
- 2009. Use of different DMSO concentrations for cryopreservation of autologous peripheral blood stem cell grafts does not have any major impact on levels of leukocyte- and platelet-derived soluble mediators. Cytotherapy. 11: 749-760. doi: 10.3109/14653240902980443
- 2009. Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia. British Journal of Haematology. 144: 53-68. doi: 10.1111/j.1365-2141.2008.07411.x
- 2009. Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators. British Journal of Haematology. 144: 53-68. doi: 10.1111/j.1365-2141.2008.07411.x
- 2009. Long-term cryopreservation of autologous stem cell grafts: a clinical and experimental study of hematopoietic and immunocompetent cells. Transfusion. 49: 1709-1719. doi: 10.1111/j.1537-2995.2009.02180.x
- 2009. The protein kinase C agonist PEP005 increases NF-kB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells. British Journal of Haematology. 145: 761-774. doi: 10.1111/j.1365-2141.2009.07691.x
- 2009. Heat shock protein 90-a potential target in the treatment of human acute myelogenous leukemia. Current Cancer Drug Targets. 9: 761-776.
- 2009. Nuclear Factor-kappaB Signaling: A Contributor in Leukemogenesis and a Target for Pharmacological Intervention in Human Acute Myelogenous Leukemia. Critical reviews in oncogenesis. 15: 1-41.
- 2008. Anticancer Immunotherapy in Combination with Proapoptotic Therapy. Current Cancer Drug Targets. 8: 666-675. doi: 10.2174/156800908786733496
- 2008. Chemokine receptor expression by circulating T cells derived from acute leukemia patients with severe chemotherapy-induced cytopenia express a wide range of chemokine receptors. Haematologica. 93: 456-457.
- 2008. Circulating T cells derived from acute leukemia patients with severe therapy-induced cytopenia express a wide range of chemokine receptors. Hematology. 13: 329-332. doi: 10.1179/102453308X343491
- 2008. In vitro induction of a dendritic cell phenotype in primary human acute myelogenous leukemia (AML) blasts alters the chemokine release profile and increases the levels of T cell chemotactic CCL17 and CCL22. Journal of Interferon and Cytokine Research. 28: 297-310. doi: 10.1089/jir.2007.0052
- 2007. Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cells. Current Pharmaceutical Biotechnology. 8: 388-400. doi: 10.2174/138920107783018417
- 2007. T cells remaining after intensive chemotherapy for acute myelogenous leukemia show a broad cytokine release profile including high levels of interferon-gamma that can be further increased by a novel protein kinase C agonist PEP005. Cancer Immunology and Immunotherapy. 56: 013-925. doi: 10.1007/s00262-006-0236-5
- 2007. Circulating T cells in patients with untreated acute myelogenous leukemia are heterogeneous and can be activated through the CD3/TCR complex. Hematology. 12: 199-207. doi: 10.1080/10245330701255163
- 2007. The Immunological Dilemma: Cellular Innate and Adaptive Immune Response Versus Human Acute Myeloid Leukemia. The Open Hematology Journal. 1: 1-14. doi: 10.2174/1874276900701010001
- 2007. Effects of interferon gamma on native human acute myelogenous leukaemia cells. Cancer Immunology and Immunotherapy. 56: 13-24. doi: 10.1007/s00262-006-0159-1
- 2007. Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients. European Journal of Haematology. 79: 210-225. doi: 10.1111/j.1600-0609.2007.00899.x
- 2007. In vitro induction of a dendritic cell phenotype in primary human acute myelogenous leukemia (AML) blasts: The chemokine release profile of the AML dendritic cells depends on the experimental protocol. Haematologica. 92: 485-485.
- 2007. The protein kinase C activator PEP005 increases the chemokine release in native acute myelogenous leukemia (AML) blasts. Experimental Hematology. 35: 87-87.
- 2007. The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. British Journal of Haematology. 136: 814-828. doi: 10.1111/j.1365-2141.2007.06504.x
- 2006. Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2 : Bax ratio and low levels of heat shock protein 70 and 90. Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis. 30: 1531-1540.
- 2004. Characterization of ribosomal P autoantibodies in relation to cell destruction and autoimmune disease. Scandinavian Journal of Immunology. 60: 189-198. doi: 10.1111/j.0300-9475.2004.01450.x
Reports and theses
- 2007. Immunological aspects of acute myelogenous leukemia. University of Bergen, Bergen: University of Bergen.
More information in national current research information system (CRIStin)